Mehmet Kanbay
Mehmet Kanbay is an expert in Nephrology at Koç University Hospital (Turkey). As of October 2026, ScienceLeadR ranks Mehmet Kanbay in the top 1% of experts worldwide for Kidney Transplantation, Renal Insufficiency and Hypertension. Mehmet Kanbay has authored 580 publications, the most recent in 2026, and is an investigator in 6 clinical trials. SLR score: 2,156 (community average: 125). How the SLR is computed.
LeadR Profile
Nephrology
Subspecialties: Transplantation - Urology - Endocrinology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2004 - 2026
Number : 580
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Aldosterone and Residual Cardiorenal Risk: Pathophysiology and Emerging Therapeutic Strategies. PMID 42886065 — aldosterone, albuminuria, kidney, renin, receptors, mineralocorticoid, angiotensins, nephrology, therapeutics, kidney transplantation, mineralocorticoid receptor antagonists | Nephrol Dial Transplant | 2026 | 0 |
| Targeting calciphylaxis: the emergence of vitamin K as a potential treatment. PMID 42877409 — calciphylaxis, vitamins, vitamin k, therapeutics, vascular calcification | Clin Kidney J | 2026 | 0 |
| Ten tips to reduce fracture risk by non-pharmacologic interventions in CKD-associated osteoporosis. PMID 42824698 — kidney diseases, portasystemic shunt, transjugular intrahepatic, kidney, osteoporosis, calcium, prevalence, kidney failure, chronic, therapeutics | Clin Kidney J | 2026 | 0 |
| Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes. PMID 42697978 — kidney diseases, c-reactive protein, kidney, therapeutics | Nat Rev Nephrol Top journal | 2026 | 1 |
| Kidney outcomes and safety of sodium-glucose cotransporter-2 inhibitor therapy in autosomal dominant polycystic kidney disease: systematic review and meta-analysis. PMID 42586506 — diabetes mellitus, kidney diseases, sodium-glucose transport proteins, sodium-glucose transporter 2 inhibitors, safety, kidney, therapeutics, polycystic kidney diseases, polycystic kidney, autosomal dominant | Diabetes Res Clin Pract | 2026 | 0 |
Clinical Studies 6
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
LeadR Networks
Main global connection map